Cassadie Moravek

3.8k total citations
14 papers, 674 citations indexed

About

Cassadie Moravek is a scholar working on Oncology, Cancer Research and Economics and Econometrics. According to data from OpenAlex, Cassadie Moravek has authored 14 papers receiving a total of 674 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Cancer Research and 5 papers in Economics and Econometrics. Recurrent topics in Cassadie Moravek's work include Pancreatic and Hepatic Oncology Research (10 papers), Cancer Genomics and Diagnostics (7 papers) and Economic and Financial Impacts of Cancer (5 papers). Cassadie Moravek is often cited by papers focused on Pancreatic and Hepatic Oncology Research (10 papers), Cancer Genomics and Diagnostics (7 papers) and Economic and Financial Impacts of Cancer (5 papers). Cassadie Moravek collaborates with scholars based in United States, Austria and Canada. Cassadie Moravek's co-authors include Alok A. Khorana, Shannon McKernin, Manish A. Shah, Ignacio Garrido‐Laguna, Michelle Lau, Mehmet Sitki Copur, Daniel A. Laheru, Eileen M. O’Reilly, Philip A. Philip and Davendra Sohal and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and The American Journal of Gastroenterology.

In The Last Decade

Cassadie Moravek

12 papers receiving 661 citations

Peers

Cassadie Moravek
Alice Zervoudakis United States
Nancy Watroba United States
Sanjun Cai China
Virginia Arrazubi Spain
Isabelle Baumgaertner France
Shaan Dudani Canada
Maria Biglietto Italy
Shan Zheng China
E. del Barco Spain
Alice Zervoudakis United States
Cassadie Moravek
Citations per year, relative to Cassadie Moravek Cassadie Moravek (= 1×) peers Alice Zervoudakis

Countries citing papers authored by Cassadie Moravek

Since Specialization
Citations

This map shows the geographic impact of Cassadie Moravek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cassadie Moravek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cassadie Moravek more than expected).

Fields of papers citing papers by Cassadie Moravek

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cassadie Moravek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cassadie Moravek. The network helps show where Cassadie Moravek may publish in the future.

Co-authorship network of co-authors of Cassadie Moravek

This figure shows the co-authorship network connecting the top 25 collaborators of Cassadie Moravek. A scholar is included among the top collaborators of Cassadie Moravek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cassadie Moravek. Cassadie Moravek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Picozzi, Vincent J., Anna M. Varghese, Paul E. Oberstein, et al.. (2025). Pamrevlumab plus nab-paclitaxel/gemcitabine (Pam + GA) as first- and second-line therapy in metastatic pancreatic cancer (mPDAC): Results from Precision Promise (PrP) Bayesian platform trial.. Journal of Clinical Oncology. 43(4_suppl). 673–673. 1 indexed citations
2.
Oberstein, Paul E., Andrea Wang‐Gillam, Anna M. Varghese, et al.. (2024). Precision Promise (PrP) Bayesian platform trial for metastatic pancreatic cancer (mPDAC): Results of the first experimental arm, SM-88 as second line therapy.. Journal of Clinical Oncology. 42(3_suppl). 675–675.
3.
Rosenzweig, Allison, Cassadie Moravek, & Lynn M. Matrisian. (2022). More efficient clinical trials in pancreatic cancer: develop better treatment options, faster. Journal of Cancer Metastasis and Treatment. 6. 46–46. 1 indexed citations
4.
Garcia, José M., Richard F. Dunne, Lisa Martin, et al.. (2022). Addressing unmet needs for people with cancer cachexia: recommendations from a multistakeholder workshop. Journal of Cachexia Sarcopenia and Muscle. 13(2). 1418–1425. 21 indexed citations
5.
Gupta, Arjun, Cassadie Moravek, Lynn M. Matrisian, et al.. (2021). Leveraging patient‐reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experience. Cancer Medicine. 10(20). 7152–7161. 8 indexed citations
6.
Friedman, Sue, Ronit I. Yarden, E. Kuhn, et al.. (2020). Using consistent terms in precision medicine to eliminate patient confusion.. Journal of Clinical Oncology. 38(15_suppl). e24164–e24164. 4 indexed citations
7.
Sohal, Davendra, Erin B. Kennedy, Pelin Cinar, et al.. (2020). Metastatic Pancreatic Cancer: ASCO Guideline Update. Journal of Clinical Oncology. 38(27). 3217–3230. 180 indexed citations
8.
Gupta, Arjun, Cassadie Moravek, Lynn M. Matrisian, et al.. (2020). Leveraging patient-reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experience.. Journal of Clinical Oncology. 38(29_suppl). 154–154. 3 indexed citations
9.
Khorana, Alok A., Shannon McKernin, Jordan Berlin, et al.. (2019). Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology. 37(23). 2082–2088. 130 indexed citations
10.
Matrisian, Lynn M., Edik M. Blais, Emily E. Lyons, et al.. (2019). Precision Oncology for Pancreatic Cancer across the United States: the Know Your Tumor ® experience. Annals of Oncology. 30. vi30–vi30.
11.
Barkin, Jodie A., William Hoos, Cassadie Moravek, et al.. (2019). Frequency of Appropriate Use of Pancreatic Enzyme Replacement Therapy and Symptomatic Response in Pancreatic Cancer Patients. Pancreas. 48(6). 780–786. 32 indexed citations
12.
Stoffel, Elena M., Shannon McKernin, Randall E. Brand, et al.. (2018). Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. Journal of Clinical Oncology. 37(2). 153–164. 104 indexed citations
13.
Sohal, Davendra, Erin B. Kennedy, Alok A. Khorana, et al.. (2018). Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology. 36(24). 2545–2556. 188 indexed citations
14.
Rahib, Lola, Jodie A. Barkin, William Hoos, et al.. (2017). Frequency of Appropriate Use of Pancreatic Enzyme Replacement Therapy (PERT) and Symptomatic Response in Pancreatic Cancer Patients. The American Journal of Gastroenterology. 112. S23–S23. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alice Zervoudakis Breakdown of academic impact, for papers by Nancy Watroba Breakdown of academic impact, for papers by Sanjun Cai Breakdown of academic impact, for papers by Virginia Arrazubi Breakdown of academic impact, for papers by Isabelle Baumgaertner Breakdown of academic impact, for papers by Shaan Dudani Breakdown of academic impact, for papers by Maria Biglietto Breakdown of academic impact, for papers by Shan Zheng Breakdown of academic impact, for papers by E. del Barco
Rankless by CCL
2026